Investing.com — While the main story this week was the Federal Reserve’s more cautious path for rate cuts next year, there were plenty of individual stocks and sector stories that resulted in volatility for some big names. Here are Investing.com’s stocks of the week: Micron Technology (NASDAQ:), Novo Nordisk (NYSE:), MicroStrategy and Coinbase (NASDAQ:).
Micron Technology
Micron Technology shares tumbled more than 16% Thursday after the company reported its latest quarterly earnings, with its outlook disappointing investors.
While its Q1 EPS of $1.79 was $0.06 better than the analyst estimate of $1.73 and revenue for the quarter came in at $8.71 billion, above the consensus estimate of $8.68 billion, Micron forecast quarterly revenue and profit below Wall Street estimates after the close on Wednesday.
For Q2 2025, Micron sees its EPS between $1.33 and $1.53, below the consensus of $1.97. Meanwhile, revenue for the quarter is expected to be between $7.7 billion and $8.1 billion, lower than the consensus estimate of $8.97 billion.
Following the earnings release, JPMorgan lowered its target for the stock to $145 from $180, telling investors that “despite the near-term weakness, we continue to believe the down-cycle in memory will be short-lived.”
The bank expects market conditions to improve in the latter part of 2025 as “leading-edge DRAM supply remains tight and strong AI server demand continues to drive growth in HBM/DDR5.”
Novo Nordisk
It was a bad day on Friday for Novo Nordisk shares with the stock (at the time of writing) down 17.4% on the day.
The decline comes after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed investors.
The company’s REDEFINE 1 trial showed that people treated with CagriSema, a combination of cagrilintide and semaglutide, achieved a weight loss of 22.7% after 68 weeks.
However, while that was statistically significant, it fell short of the target of 25%.
Following the news, rival Eli Lilly’s shares jumped.
Reacting to the results, analysts at Wolfe Research said: “While we didn’t expect CagriSema to be a formidable competitor to Lilly’s Zepbound, we now see Lilly in a true class of its own with Zepbound, orforglipron and retatrutide.”
MicroStrategy, Coinbase
After climbing to over $108,000 earlier in the week, the price of fell from Wednesday onwards, touching a low of $92,118 on Friday.
While MSTR and COIN are up on Friday, +8.1% and +1%, respectively, both names have declined for most of this week. MicroStrategy is down around 14% over the last five days, while Coinbase has declined over 11%.
Looking at Bitcoin itself, while the price plunged initially on Friday it has clawed back some ground. As of 13:58 ET, it is trading at $97,075.
